• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002317.SZ
Share

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Stocks

CN¥ 26.84Last Updated 26.10.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 3.31B

CN¥ 26.84
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Guangdong Zhongsheng Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company actively involved in the entire lifecycle of drug development, from research and development to manufacturing and commercialization. Its product portfolio encompasses both traditional Chinese medicines (TCM) and modern chemical pharmaceuticals. The company's robust research and development initiatives are directed towards creating solutions for a wide array of health conditions, specifically targeting ophthalmological, cardiovascular, cerebrovascular, respiratory, digestive, diabetic, oncological, and age-related degenerative diseases. Established in 1979, the company maintains its primary operations from its headquarters in Dongguan, China.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 002317.SZ is 35.0 and suggests 34.8% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.10.2026 01:51

Anthropic Disclosed Its Reliance on Google, Amazon, and Microsoft Ahead of Its IPO. What Is the Risk?

27.10.2026 00:38

Microsoft is cutting costs: 60,000 employees have been offered voluntary separation

27.10.2026 00:18

"If the bubble bursts, it will all start with debt": How the problems of the neo-claws threaten the S&P 500

26.10.2026 23:40

Buyers of the foldable iPhone have complained about screen damage. How does this affect the stock price?

26.10.2026 23:02

One of Wall Street’s biggest bulls drops overweight call on stocks ahead of midterms

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026